Ramon Güimil García

Director Técnico/Científico/I+D en Hummingbird Diagnostics GmbH .

Consumer Services

Health Technology

Perfil

Ramon Güimil García is currently working as Vice President-Research & Development at Hummingbird Diagnostics GmbH.
Prior to this, he worked as Principal at The European Molecular Biology Laboratory and Nucleic Acid Synthesis Group.

Cargos activos de Ramon Güimil García

Empresas	Cargo	Inicio
Hummingbird Diagnostics GmbH Hummingbird Diagnostics GmbH Medical SpecialtiesHealth Technology Hummingbird Diagnostics GmbH specializes in patient-friendly diagnostics for early disease detection, personalized medicine, and lifetime health monitoring. Hummingbird Diagnostics is based in Heidelberg, DE and was founded by Jochen Kohlhaas and Karoly Nikolich. The German company uses liquid biopsies based on miRNA biomarkers to detect diseases such as lung cancer, melanoma, breast cancer, multiple sclerosis, Alzheimer's, Parkinson's, heart diseases, and IBD. Jochen Kohlhaas has been the CEO since incorporation.	Director Técnico/Científico/I+D	30/11/2009

Todos los cargos activos de Ramon Güimil García

Antiguos cargos conocidos de Ramon Güimil García.

Empresas	Cargo	Fin
The European Molecular Biology Laboratory	Corporate Officer/Principal	-
Nucleic Acid Synthesis Group	Corporate Officer/Principal	-

Ver el detalle de la experiencia de Ramon Güimil García.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Ramon Güimil García.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	2
Hummingbird Diagnostics GmbH Hummingbird Diagnostics GmbH Medical SpecialtiesHealth Technology Hummingbird Diagnostics GmbH specializes in patient-friendly diagnostics for early disease detection, personalized medicine, and lifetime health monitoring. Hummingbird Diagnostics is based in Heidelberg, DE and was founded by Jochen Kohlhaas and Karoly Nikolich. The German company uses liquid biopsies based on miRNA biomarkers to detect diseases such as lung cancer, melanoma, breast cancer, multiple sclerosis, Alzheimer's, Parkinson's, heart diseases, and IBD. Jochen Kohlhaas has been the CEO since incorporation.	Health Technology
Nucleic Acid Synthesis Group